Indicated for the treatment of: Advanced Renal Cell Carcinoma (RCC): In patients who have received prior anti-angiogenic therapy. Hepatocellular Carcinoma (HCC): In patients who have been previously treated with Sorafenib. Differentiated Thyroid Cancer.

Dosage and administration

Strength: 60 mg tablet. Standard Starting Dose: 60 mg once daily. Dose reduction to 40 mg or 20 mg may be required depending on individual tolerability. ⚠️ ADMINISTRATION (Fasting Required): 🚫 Do NOT eat for at least 2 hours before taking the tablet. 🚫 Do NOT eat for at least 1 hour after taking the tablet. Swallow whole with a full glass of water.

Recent history of severe hemorrhage or gastrointestinal perforations/fistulas. Severe hepatic impairment. Pregnancy and breastfeeding. Surgery Warning: Discontinue treatment at least 28 days prior to scheduled surgery due to wound healing complications.

Common adverse reactions requiring management: Diarrhea: Very common. Stay hydrated. Palmar-plantar erythrodysesthesia (Hand-Foot Syndrome): Pain/redness on palms and soles. Hypertension: Monitor blood pressure regularly. Fatigue and decreased appetite.

Cazanat — Cabozantinib 60 mg, 30 pcs, Natco

100% original product

Active ingredient

Cabozantinib

Manufacturer

Natco

Dosage 60 mg

Dosage form Tablets

Tablets per pack 30

Cazanat (Cabozantinib) 60 mg

Name: Cazanat
Brand: Natco
SKU: PROD-77
Price: 5494 UAH
Availability: InStock

5494₴ ~~6153₴~~ -11%

Cazanat 60 mg is a potent multi-kinase inhibitor. Active ingredient: Cabozantinib (60 mg).

Manufacturer: Natco Pharma (India). Generic equivalent of Cabometyx.

Triple-Blockade Mechanism:

Cazanat targets VEGFR, MET, and AXL. Targeting MET and AXL is crucial because tumors use these pathways to develop resistance to standard therapies. By blocking them, Cazanat works where other drugs fail, re-sensitizing the tumor to treatment.

✅ Clinical Status: A leading second-line therapy for advanced kidney and liver cancers.

Indicated for the treatment of:

Advanced Renal Cell Carcinoma (RCC): In patients who have received prior anti-angiogenic therapy.
Hepatocellular Carcinoma (HCC): In patients who have been previously treated with Sorafenib.
Differentiated Thyroid Cancer.

Strength: 60 mg tablet.

Standard Starting Dose: 60 mg once daily. Dose reduction to 40 mg or 20 mg may be required depending on individual tolerability.

⚠️ ADMINISTRATION (Fasting Required):

🚫 Do NOT eat for at least 2 hours before taking the tablet.
🚫 Do NOT eat for at least 1 hour after taking the tablet.

Swallow whole with a full glass of water.

Recent history of severe hemorrhage or gastrointestinal perforations/fistulas.
Severe hepatic impairment.
Pregnancy and breastfeeding.
Surgery Warning: Discontinue treatment at least 28 days prior to scheduled surgery due to wound healing complications.

Common adverse reactions requiring management:

Diarrhea: Very common. Stay hydrated.
Palmar-plantar erythrodysesthesia (Hand-Foot Syndrome): Pain/redness on palms and soles.
Hypertension: Monitor blood pressure regularly.
Fatigue and decreased appetite.

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 02.03.2026

Active ingredient

Cabozantinib

Manufacturer

Natco

Dosage 60 mg

Dosage form Tablets

Tablets per pack 30

100% original product

Delivery across Ukraine

Alternatives

What Customers Say

No reviews yet

Your review can be the first!

Cazanat (Cabozantinib) 60 mg

Similar products

Caboxen 80

Caboxen 20

What Customers Say

No reviews yet

Contact us

Request a call